Feedback PLC Directorate Change (2300V)
20 July 2018 - 4:00PM
UK Regulatory
TIDMFDBK
RNS Number : 2300V
Feedback PLC
20 July 2018
20 July 2018
Feedback plc
Directorate Change - Chief Executive Officer
Feedback plc (AIM: FDBK, 'Feedback' or the 'Company'), the
specialist medical imaging technology company, announces that David
Crabb is stepping down as Chief Executive Officer in order to
devote more time to his other business interests. He will leave the
Company with immediate effect.
During his tenure, David has simplified the Company's structure
and directed resources to deliver more effective products and
services to its current customer base. This places it in a stronger
position to grow organically as it pursues strategic partnerships
with larger companies within the pharmaceutical industry.
The Company has initiated a search for a new Chief Executive
Officer to take Feedback through its next phase of growth. In the
meantime, Dr Alastair Riddell will assume the role of Executive
Chairman. A further announcement will be made in due course.
Dr. Riddell said: "On behalf of the Board I would like to
acknowledge and thank David for his contribution to Feedback. We
wish him well with his future endeavours."
David Crabb said: "It has been a pleasure to contribute to the
direction of the Company and I wish the team the best for the
future."
For further information, please contact:
Feedback plc +44 (0)1954 718072
Alastair Riddell, Executive Chairman IR@fbk.com
Allenby Capital Limited (Nominated Adviser
and Joint Broker)
David Worlidge / Asha Chotai +44 (0)20 3328 5656
Peterhouse Corporate Finance Ltd (Joint
Broker)
Lucy Williams / Duncan Vasey +44 (0)20 7469 0936
Instinctif Partners +44 (0)20 7457 2020
Melanie Toyne Sewell / Rozi Morris feedbackplc@instinctif.com
Notes to editors
About Feedback plc
Feedback plc is a specialist medical imaging technology company.
It develops software and systems that provide innovative techniques
and improved workflows for practitioners involved in medical
research and treating patients. TexRAD(R) , the Company's patented
quantitative image texture analysis technology, has the potential
to assist clinicians in diagnosis, prognosis and treatment of
patients with cancer and is currently installed in over 50 of the
world's leading research institutions across Europe, North America,
Asia and Australasia. The Cadran platform provides a suite of
medical imaging tools for decision support. The Cadran range
includes the picture archiving communication system (PACS) to
provide decision support for scan analysis, diagnostic workstations
which provide secure remote access to view scans on demand, and
products to securely share and transport patient data.
For more information visit www.fbk.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOARLMLTMBIBBJP
(END) Dow Jones Newswires
July 20, 2018 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Apr 2024 to May 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From May 2023 to May 2024